These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12149960)

  • 1. Enhancement of dissolution rate and anti-inflammatory effects of piroxicam using solvent deposition technique.
    Barzegar-Jalali M; Maleki N; Garjani A; Khandar AA; Haji-Hosseinloo M; Jabbari R; Dastmalchi S
    Drug Dev Ind Pharm; 2002 Jul; 28(6):681-6. PubMed ID: 12149960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissolution, bioavailability and ulcerogenic studies on piroxicam-nicotinamide solid dispersion formulations.
    Verma MM; Kumar MT; Balasubramaniam J; Pandit JK
    Boll Chim Farm; 2003 Apr; 142(3):119-24. PubMed ID: 12806831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid-state dependent dissolution and oral bioavailability of piroxicam in rats.
    Lust A; Laidmäe I; Palo M; Meos A; Aaltonen J; Veski P; Heinämäki J; Kogermann K
    Eur J Pharm Sci; 2013 Jan; 48(1-2):47-54. PubMed ID: 23085546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissolution properties of piroxicam powders and capsules as a function of particle size and the agglomeration of powders.
    Swanepoel E; Liebenberg W; de Villiers MM; Dekker TG
    Drug Dev Ind Pharm; 2000 Oct; 26(10):1067-76. PubMed ID: 11028221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
    Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
    Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems.
    Pan RN; Chen JH; Chen RR
    Drug Dev Ind Pharm; 2000 Sep; 26(9):989-94. PubMed ID: 10914324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dissolution enhancement of piroxicam in its physical mixtures and solid dispersion formulations using gluconolactone and glucosamine hydrochloride as potential carriers.
    Al-Hamidi H; Obeidat WM; Nokhodchi A
    Pharm Dev Technol; 2015 Jan; 20(1):74-83. PubMed ID: 24392858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of solubility, dissolution release profile and reduction in ulcerogenicity of piroxicam by inclusion complex with skimmed milk.
    Sanka K; Munjulury VS; Mohd AB; Diwan PV
    Drug Deliv; 2014 Nov; 21(7):560-70. PubMed ID: 24266528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissolution enhancement and formulation of rapid-release lornoxicam mini-tablets.
    Tawfeek HM; Saleem IY; Roberts M
    J Pharm Sci; 2014 Aug; 103(8):2470-83. PubMed ID: 24995853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of piroxicam from self-emulsifying lipospheres formulated with homolipids extracted from Capra hircus.
    Attama AA; Mpamaugo VE
    Drug Deliv; 2006; 13(2):133-7. PubMed ID: 16423801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules.
    Piscitelli DA; Bigora S; Propst C; Goskonda S; Schwartz P; Lesko LJ; Augsburger L; Young D
    Pharm Dev Technol; 1998 Nov; 3(4):443-52. PubMed ID: 9834946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced bioavailability of piroxicam via salt formation with ethanolamines.
    Gwak HS; Choi JS; Choi HK
    Int J Pharm; 2005 Jun; 297(1-2):156-61. PubMed ID: 15907602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced oral bioavailability of piroxicam in rats by hyaluronate microspheres.
    Piao MG; Kim JH; Kim JO; Lyoo WS; Lee MH; Yong CS; Choi HG
    Drug Dev Ind Pharm; 2007 Apr; 33(4):485-91. PubMed ID: 17523012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
    Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
    J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethyl cellulose nanoparticles as a platform to decrease ulcerogenic potential of piroxicam: formulation and in vitro/in vivo evaluation.
    El-Habashy SE; Allam AN; El-Kamel AH
    Int J Nanomedicine; 2016; 11():2369-80. PubMed ID: 27307735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and evaluation of piroxicam-HPMCAS solid dispersions for ocular use.
    Jachowicz R; Czech A
    Pharm Dev Technol; 2008; 13(6):495-504. PubMed ID: 18720246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melt sonocrystallized piroxicam for oral delivery: particle characterization, solid state analysis, and pharmacokinetics.
    Gupta PS; Sharma V; Pathak K
    Expert Opin Drug Deliv; 2013 Jan; 10(1):17-32. PubMed ID: 23102052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoemulsifying drug delivery system to improve the bioavailability of piroxicam.
    Motawea A; Borg T; Tarshoby M; Abd El-Gawad AE
    Pharm Dev Technol; 2017 May; 22(3):445-456. PubMed ID: 27583581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piroxicam loaded polymer hybrid microspheres based tablets with modified release kinetics: Development, characterization and in vivo evaluation.
    Hamid HA; Khan S; Noor Shah SM; Asghar M; Shahid M; Hussain Z; Sohail M; Khan BA; Amin F; Jan SU; Elhissi A; Shah SMH; Minhas MU; Shah SWA; Ahmad N
    Pak J Pharm Sci; 2021 Jan; 34(1(Supplementary)):327-335. PubMed ID: 34275858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
    Maghsoodi M; Sadeghpoor F
    Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.